Key result
A 12-month Comprehensive Program of Cognitive Training prevented significant cognitive decline in Alzheimer's patients, with no significant differences in MMSE, IADL, and GDS from baseline to 12 months.
Why the study?
Most non-pharmacological interventions for Alzheimer's disease did not last beyond six months, leaving the effects of such programs after six months of treatment poorly understood.
Does a twelve-month Comprehensive Program of Cognitive Training (CPCT) prevent cognitive decline in Alzheimer's disease patients?
Does a twelve-month Comprehensive Program of Cognitive Training (CPCT) prevent cognitive decline in Alzheimer's disease patients?
A 12-month comprehensive cognitive training program may delay cognitive decline in Alzheimer's patients, maintaining baseline function over one year.
May support cognitive training to stabilize cognition in AD; leaves open confirmation by randomized trials.
Research has shown that non-pharmacological therapies can be useful in the treatment of Alzheimer’s disease (AD), significantly delaying cognitive decay. However, most AD interventions did not last beyond six months. Hence, little is known about the effect of these programs in the AD patients after six months of treatment. The purpose of this study was to evaluate the efficacy of the twelve-month Comprehensive Program of Cognitive Training (CPCT) for a sample of AD patients and to compare the results with the average annual rate of change. Thirty-nine AD patients participated in the study. The CPCT consists of a set of cognitive stimulations, intervention in activities of daily life (ADL), and motor training for 12 months. All patients were evaluated at baseline and in three-month intervals via the Mini Mental State Examination (MMSE), the Cambridge Cognitive Examination (CAMCOG), the Lawton Instrumental Activities of Daily Living Scale (IADL), and the Global Deterioration Scale (GDS). After CPCT implementation, there were no significant differences in the MMSE, IADL, and GDS evaluations between baseline and twelve months. Concerning the CAMCOG evaluation, there was no significant difference between the baseline and sixth-month assessments. Overall, the participants’ cognitive functioning did not decline when compared to the average annual rate of change. The CPCT extends the benefit of non-pharmacological interventions for AD patients to twelve months. Its implementation might provide the patients’ relatives with some guarantee concerning the delay of the disease. Future research may investigate the efficacy of the CPCT in comparison with a control group and over a more extended period.
No takes yet. Share an insight, caveat, or question.
Rodríguez-Mora et al. (2020) studied Alzheimer's disease (n=39). Comprehensive Program of Cognitive Training (CPCT) vs. Average annual rate of change (no concurrent control group) was evaluated on Cognitive functioning evaluated via MMSE, CAMCOG, IADL, and GDS. A 12-month Comprehensive Program of Cognitive Training prevented significant cognitive decline in Alzheimer's patients, with no significant differences in MMSE, IADL, and GDS from baseline to 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: